Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.65 |
| ▸ | AMD1 | P17707 | 2/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489379 | 0.91 | EHMT1 (0.73) | AMD1ADORA3DOT1LDPP4MEN1 | |
| SCHEMBL7622931 | 0.91 | EHMT1 (0.73) | AMD1ADORA3DOT1LDPP4MEN1 | |
| SCHEMBL2115819 | 0.88 | EHMT1 (0.71) | EGFRERBB2AMD1ADORA3DOT1L | |
| SCHEMBL2829517 | 0.86 | EHMT1 (0.78) | EGFRERBB2AMD1ADORA3DOT1L | |
| SCHEMBL505376 | 0.85 | EGFR (0.71) | EGFRERBB2AMD1ADORA3DOT1L | |
| SCHEMBL10665708 | 0.85 | EHMT1 (0.70) | EGFRERBB2AMD1ADORA3DOT1L | |
| SCHEMBL1490898 | 0.85 | EGFR (0.71) | EGFRERBB2AMD1ADORA3DOT1L | |
| SCHEMBL30893122 | 0.84 | EGFR (0.84) | EGFRERBB2AMD1ADORA3DOT1L | |
| SCHEMBL5695357 | 0.84 | EGFR (0.84) | EGFRERBB2AMD1ADORA3DOT1L | |
| SCHEMBL2829298 | 0.83 | EGFR (0.62) | EGFRERBB2AMD1ADORA3DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |
| US-4948783-A | ORALLY ADMINISTERING ADENOSINE OR DERIVATIVE | KABUSHIKI KAISYA ADVANCE KAIHATSU KENKYUJO (JP) | 1990-08-14 | — | — | US | claimed |
| JP-5208993-A | — | — | None | — | — | JP | disclosed |
| JP-8183737-A | — | — | None | — | — | JP | disclosed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| JP-H08183737-A | ALCOHOL ABSORPTION INHIBITOR | ADVANCE CO LTD | 1996-07-16 | — | — | JP | disclosed |
| JP-H05208993-A | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ISCHEMIA | BIORESEARCH SPA | 1993-08-20 | — | — | JP | disclosed |
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | disclosed |
| EP-0191561-B1 | ANTICARIOGENIC OR ANTIPERIODONTITIC AGENT | KABUSHIKI KAISYA ADVANCE (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-4948783-A | ORALLY ADMINISTERING ADENOSINE OR DERIVATIVE | KABUSHIKI KAISYA ADVANCE KAIHATSU KENKYUJO (JP) | 1990-08-14 | — | — | US | disclosed |
| EP-0191561-A2 | Anticariogenic or antiperiodontitic agent | KABUSHIKI KAISYA ADVANCE (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | EGFR 3632/4885ERBB2 4303/4885AMD1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.